Prosight Management, LP Cognition Therapeutics Inc Transaction History

Prosight Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.5 - $3.45 $179,823 - $413,592	-119,882 Reduced 49.93%	120,198 $254,000
Q1 2022 May 16, 2022	SELL	$2.41 - $6.9 $149,176 - $427,103	-61,899 Reduced 20.5%	240,080 $660,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $12.98 $1.54 Million - $3.92 Million	301,979 New	301,979 $1.91 Million

9.4M

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $43.4M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.